Pfizer hints at acquisitions to boost obesity pipeline after trial setback

JHVEPhoto/iStock Editorial via Getty Images With the company’s Q1 2025 results on Tuesday, Pfizer ( NYSE: PFE ) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies, to the pipeline, following a major trial setback this month. PFE shares came under pressure.